In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Servier SA

www.servier.com

Latest From Servier SA

Philogen Raises €62m To Advance Pipeline, Expand GMP Capacity

Philogen CEO Dario Neri tells Scrip the company he co-founded now has two oncology products in Phase III development and might consider partnering them for certain indications.

Clinical Trials Commercial

How Abbott Is Making Incremental Innovation Count For Patients

Abbott’s innovation and development center in Mumbai has made significant progress in shaping incremental but impactful innovations for India and some international markets. A once-daily formulation of heart failure drug ivabradine has caught the attention of the innovator company too.

Research & Development Innovation

Galapagos Flies As Filgotinib Soars In FINCH Studies

More evidence of its strong safety profile suggests that the Belgian biotech's oral selective JAK1 inhibitor partnered with Gilead will be able to break into the crowded RA market.

Safety Immune Disorders

Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine

While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.

Business Strategies Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register